1. Home
  2. SRPT vs OXLCO Comparison

SRPT vs OXLCO Comparison

Compare SRPT & OXLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • OXLCO
  • Stock Information
  • Founded
  • SRPT 1980
  • OXLCO N/A
  • Country
  • SRPT United States
  • OXLCO United States
  • Employees
  • SRPT N/A
  • OXLCO N/A
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • OXLCO Investment Managers
  • Sector
  • SRPT Health Care
  • OXLCO Finance
  • Exchange
  • SRPT Nasdaq
  • OXLCO Nasdaq
  • Market Cap
  • SRPT 1.7B
  • OXLCO N/A
  • IPO Year
  • SRPT 1997
  • OXLCO N/A
  • Fundamental
  • Price
  • SRPT $19.23
  • OXLCO $23.25
  • Analyst Decision
  • SRPT Buy
  • OXLCO
  • Analyst Count
  • SRPT 25
  • OXLCO 0
  • Target Price
  • SRPT $61.57
  • OXLCO N/A
  • AVG Volume (30 Days)
  • SRPT 7.9M
  • OXLCO N/A
  • Earning Date
  • SRPT 08-06-2025
  • OXLCO N/A
  • Dividend Yield
  • SRPT N/A
  • OXLCO N/A
  • EPS Growth
  • SRPT N/A
  • OXLCO N/A
  • EPS
  • SRPT N/A
  • OXLCO N/A
  • Revenue
  • SRPT $2,233,371,000.00
  • OXLCO N/A
  • Revenue This Year
  • SRPT $26.87
  • OXLCO N/A
  • Revenue Next Year
  • SRPT $3.15
  • OXLCO N/A
  • P/E Ratio
  • SRPT N/A
  • OXLCO N/A
  • Revenue Growth
  • SRPT 59.15
  • OXLCO N/A
  • 52 Week Low
  • SRPT $16.88
  • OXLCO N/A
  • 52 Week High
  • SRPT $154.13
  • OXLCO N/A
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 33.14
  • OXLCO 57.65
  • Support Level
  • SRPT $17.95
  • OXLCO $23.16
  • Resistance Level
  • SRPT $19.74
  • OXLCO $23.25
  • Average True Range (ATR)
  • SRPT 1.09
  • OXLCO 0.05
  • MACD
  • SRPT 0.97
  • OXLCO -0.01
  • Stochastic Oscillator
  • SRPT 80.76
  • OXLCO 55.11

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

About OXLCO Oxford Lane Capital Corp. Preferred Stock Shares 6.00% Series 2029

Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.

Share on Social Networks: